John A. Lewicki

CIK: 0001553352

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MREO

Mereo BioPharma Group plc

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

MREO
Mereo BioPharma Group plc
Feb 1, 2026
Award(A)
Share Options (Right to buy)
Direct
139.9K shares-
MREO
Mereo BioPharma Group plc
Feb 1, 2026
Award(A)
Share Options (Right to buy)
Direct
46.6K shares-
MREO
Mereo BioPharma Group plc
Feb 1, 2026
Award(A)
Share Options (Right to buy)
Direct
145K shares-
MREO
Mereo BioPharma Group plc
Jan 25, 2025
Award(A)
Share Options (Right to buy)
Direct
116K shares-
MREO
Mereo BioPharma Group plc
Sep 13, 2024
Sale(S)
Direct
10.9K shares at avg. $4.22$46K
MREO
Mereo BioPharma Group plc
Sep 12, 2024
Sale(S)
Direct
5.2K shares at avg. $4.47$23K
MREO
Mereo BioPharma Group plc
Sep 11, 2024
Exercise(M)
Direct
46K shares-

		Type	Shares	Price		Ownership
Feb 1, 2026	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	139,913	-	-	Direct
Feb 1, 2026	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	46,637	-	-	Direct
Feb 1, 2026	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	145,000	-	-	Direct
Jan 25, 2025	MREO Mereo BioPharma Group plc	Award(A) Share Options (Right to buy)	116,000	-	-	Direct
Sep 13, 2024	MREO Mereo BioPharma Group plc	Sale(S)	10,937	$4.22	$46,165	Direct
Sep 12, 2024	MREO Mereo BioPharma Group plc	Sale(S)	5,212	$4.47	$23,312	Direct
Sep 11, 2024	MREO Mereo BioPharma Group plc	Exercise(M)	46,000	-	$0	Direct

1-7 of 7 transactions

About Lewicki John A.

Lewicki John A. (SEC CIK 0001553352) files insider reports with the SEC as Chief Scientific Officer of Mereo BioPharma Group plc (MREO).

Signal8 holds 4 ownership filings by Lewicki John A., all Form 4s, filed between Sep 13, 2024 and Feb 2, 2026. Those filings report 7 transactions, from Sep 11, 2024 to Feb 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lewicki John A.'s filings is in LONDON, X0.

Recent filings by Lewicki John A.

Feb 1, 2026: Grants or awards of MREO derivative securities (3 lines, Form 4, code A).
Jan 25, 2025: Grant or award of MREO derivative securities (Form 4, code A).
Sep 13, 2024: Open-market sale of MREO shares (Form 4, code S).
Sep 12, 2024: Open-market sale of MREO shares (Form 4, code S).
Sep 11, 2024: Option exercise of MREO shares (Form 4, code M).

Other insiders filing for Mereo BioPharma Group plc (MREO)

Jacquet Pierre, Director
Yoskowitz Marc J, Director
Shames Daniel, Director
Ekblom Anders, Director
Bender Jeremy, Director
PAKIANATHAN DEEPIKA, Director

How to read Form 4 transaction codes